Orkambi (lumacaftor / ivacaftor)

pill
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Orkambi (lumacaftor / ivacaftor)

How to buy Orkambi: You can order Orkambi (lumacaftor / ivacaftor) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Vertex Pharmaceuticals
Disease Cystic Fibrosis
Indication Cystic fibrosis with F508del mutation
Mode of Action CFTR potentiator (targeted therapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Strength 200 mg / 125 mg

Who is lumacaftor / ivacaftor for?

Orkambi (lumacaftor / ivacaftor) is indicated for the treatment of cystic fibrosis (CF) in patients who are homozygous for the F508del mutation in the CFTR gene [1][2][3]. The dosage 200 mg / 125 mg it is indicated for patients who are 12 years or older [1][2][3]. The FDA only approved dosage of 100 mg/ 125 mg, is indicated for patients aged 6 to 11 years [1].

Recommended dose

Complete information about Orkambi (lumacaftor / ivacaftor)  dosage and administration can be found here: [1][2][3].
The standard dosage for patients aged 12 years or older is:
  • two tablets (each containing 200 mg of lumacaftor and 125 mg of ivacaftor) taken orally every 12 hours [1][2][3]
The standard dosage for pediatric patients aged 6 to 11 years (FDA approved only):
  • two tablets (each containing 100 mg of lumacaftor and 125 mg of ivacaftor) taken orally every 12 hours [1].
Reduce dose in patients with moderate or severe hepatic impairment. When initiating Orkambi (lumacaftor / ivacaftor) in patients taking strong CYP3A inhibitors, reduce Orkambi (lumacaftor / ivacaftor) dose for the first week of treatment [1].
Consult your treating doctor for personalised dosing.

What is lumacaftor / ivacaftor and how does it work?

Orkambi (lumacaftor / ivacaftor), a combination of two active ingredients, lumacaftor and ivacaftor, is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients who are homozygous for the F508del mutation in the CFTR gene. This is the first medicine for cystic fibrosis directed at treating the cause of the disease in people who have this specific mutation [4][5].
CF is a serious genetic disorder characterized by the formation of thick mucus that accumulates in the lungs, digestive tract and other parts of the body leading to severe respiratory and digestive problems, as well as other complications such as infections and diabetes [4]. Mutations in the CFTR gene are responsible for this disease. This gene makes a protein called ‘cystic-fibrosis transmembrane conductance regulator’ (CFTR), which is involved in regulating the production of mucus and digestive juices. These mutations reduce the number of CFTR protein channels on the cell surface, or affect the way they work. These channels are used for the transport of ions (charged atoms and molecules) in and out of cells. When the channels are defective, mucus and digestive juices can become abnormally thick and sticky [5]. Orkambi addresses this problem from two sides. One of the active substance, lumacaftor, increases the number of CFTR proteins on the cell surface and the other, ivacaftor, increases the activity of the defective CFTR protein. This normalises the transport of ions through channels making the secretions less thick [5].

What is lumacaftor / ivacaftor's approval status?

Orkambi (lumacaftor / ivacaftor) was approved by:
  • FDA (USA) on July 2, 2015 [4]
  • EMA (EU) on November 19, 2015 [5]
  • TGA (AUS) on March 3, 2016 [3]
for the treatment of cystic fibrosis (CF) in patients who are homozygous for the F508del mutation in the CFTR gene.
The approvals were based on two double-blind, placebo-controlled clinical trials involving a total of 1,108 participants with CF who were 12 years and older with the F508del mutation. In both studies, participants with CF who took Orkambi (lumacaftor / ivacaftor), two pills every 12 hours, demonstrated improved lung function compared to those who took placebo [5]The most relevant measure for the evaluation of the study results after 24 weeks was the the percentage of predicted forced expiratory volume in one second (ppFEV), which is the amount of air a person can blow out in one second divided by the expected amount, calculated by taking into account several factors such as the person's sex and height [6]After 24 weeks of treatment, patients who took Orkambi (lumacaftor / ivacaftor) had an average improvement in ppFEV of 2.41 % more than those who took placebo in the first study, and 2.65 % in the second study. Treatment with Orkambi (lumacaftor / ivacaftor) also led to a reduction of 39 % in the number of exacerbations requiring hospital admission or antibiotic therapy [5].
The most common adverse reactions were dyspnea, nasopharyngitis, nausea, diarrhea, upper respiratory tract infection, fatigue, respiration abnormal, blood creatine phosphokinase increased, rash, flatulence, rhinorrhea, influenza [1].
References
[1] Summary of Product Characteristics [FDA]: Orkambi (lumacaftor / ivacaftor), Vertex Pharmaceuticals Inc., Nov. 2016.
http://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf
[2] Summary of Product Characteristics [EMA]: Orkambi (lumacaftor / ivacaftor), Vertex Pharmaceuticals Europe Ltd., Jan. 2017.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003954/WC500197611.pdf
[3] Summary of Product Characteristics [TGA]: Orkambi (lumacaftor / ivacaftor), Vertex Pharmaceuticals (Australia) Pty Ltd, Mar. 2016.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-01411-1&d=2017061916114622483
[4] FDA News Release: FDA approves new treatment for cystic fibrosis, 02/07/2015.
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm453565.htm
[5] EMA. Human Medicines: Orkambi (lumacaftor / ivacaftor), 1/12/2015, (last update: 24/01/2017), cited on 20/06/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003954/human_med_001935.jsp&mid=WC0b01ac058001d124
[6] Naylor, M.G., et al. Recommendations for using standardised phenotypes in genetic association studies. Hum Genomics. 2009; 3 (4): 308–319.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525193/

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.